Drs. Wiley and Gardner discuss the results of the PRFOLUVAXED trial and argue that culturally competent efforts to promote influenza vaccination can mitigate racial and ethnic disparities in vaccination uptake and disease severity. Read the editorial: eviden.cc/4a0VDg7

“…sometimes individual randomization may not be feasible or optimal, prompting the consideration of a cluster-randomized trial (CRT), where groups of individuals are randomly assigned to different treatment conditions.” Learn more in the full editorial eviden.cc/4aoEpsJ

A Surgical Breakthrough for Lobar Intracerebral Hemorrhage:

A randomized trial finds improved outcomes for lobar brain hemorrhages treated with minimally invasive surgery.

jwat.ch/49FNCMh Seemant Chaturvedi NEJM

In the most comprehensive head-to-head comparison of modern AI-based LLMs for application in oncology, a significant heterogeneity in model accuracy was observed, with GPT-4 showing performance competitive with a human benchmark. nejm.ai/4aJWOAY

Original Article: “Promotion of Influenza Vaccination in the Emergency Department” by Robert M. Rodriguez, MD, et al. eviden.cc/4ajX0pI

Melanie Molina, MD MAS Kelli O'Laughlin, MD, MPH Graham Nichol PAPR Princess, MD James Ford, MD UCSF Research - Department of Emergency Medicine #EmergencyMedicine

Original Article: “CAR T-Cell Immunotherapy in Minority Patients with Lymphoma” by Drs. Guido Ghilardi, Marco Ruella, et al.: eviden.cc/3VuGgI9

Ruella Lab Penn Medicine #Oncology #DEI

“The presentations of ischemia can range from acute to subacute and mild to severe. Diagnosis of this condition may pose challenges, particularly in the early, potentially salvageable, stages of disease.” Read the review by Sheina Theodore, MD, et al.: eviden.cc/43vPd66

Original Article: “Broadening Eligibility Criteria and Diversity among Patients for Cancer Clinical Trials” by Dr. Maneet Kaur et al. eviden.cc/49eRVyg

Trevor J. Royce MD MPH #Oncology #DEI

Editorial: “Never Let a Good Outbreak Go to Waste” by Robert H. Goldstein, MD, PhD eviden.cc/4bKRGNT

#InfectiousDisease #IDTwitter

Editorial: “Vaccines for Mpox — An Unmet Global Need” by Lori E. Dodd, PhD, H. Clifford Lane, MD, and Jean-Jacques Muyembe-Tamfum, MD, PhD eviden.cc/3uMa7ko

#InfectiousDisease #IDTwitter

In the ALINA phase 3 trial of adjuvant treatment for patients with resected ALK-positive non–small-cell lung cancer, disease-free survival at 2 years was 93.6% with the ALK inhibitor alectinib and 63.7% with standard chemotherapy. Full trial results: nej.md/3VUzf3M

Gain a comprehensive understanding of how to talk with patients about their weight, how to assess obesity in patients, and how to incorporate healthy lifestyle changes. Sign up for this free webinar: nej.md/4cUkaVN

“Data-driven approaches have the potential to improve efficiency in the identification of the most important drivers of [heterogeneity of treatment effect] from RCTs.” Full article by Rishi J Desai et al.: eviden.cc/4cupGhU

Muthu Vaduganathan

Each article in this collection builds on current medical evidence — answering previously open questions, challenging current clinical practices, or creating dialogue around health policies where more evidence and study is required.

Download now: eviden.cc/49gz2e8

A 70-year-old woman sought evaluation for a sensation of something moving in her nose. The sensation began during a trip to South America. What is the differential diagnosis? Read the Morning Report by Marlene M. Speth, MD, MA, et al.: eviden.cc/3IMTx7l

A novel AI–based system provides accurate and generalizable broad-spectrum disorder detection in medical imaging. Read the Original Article by Yuwei He, PhD, et al.: nejm.ai/4aCdTfC

“Rodriguez et al. showed that culturally competent face-to-face (albeit brief) interventions with emergency department clinicians can be very impactful and lead to increased influenza vaccine uptake.” Read the full editorial: eviden.cc/4a0VDg7

Rui Wang, PhD, explains why selecting the unit of randomization is key in the design of RCTs and discusses the rationale for, as well as the potential pitfalls of, using a cluster-randomized trial design. Read the full editorial: eviden.cc/4aoEpsJ